Inventor · disambiguated record
Kevin Michael Cottrell
Also filed as: COTTRELL KEVIN · COTTRELL KEVIN M · COTTRELL KEVIN MICHAEL
52 granted patents·25 pending applications·624 citations·filing 2003–2024
98Inventor score
Top patents by PatentIndex Score
77 records- 0198US9376448B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2013·Granted Jun 28, 2016·46 cites·10 claims
- 0297US11999727B2Compounds and methods of useTANGO THERAPEUTICS INC·Filed 2022·Granted Jun 4, 2024·4 cites·30 claims
- 0397US11492350B2Compounds and methods of useTANGO THERAPEUTICS INC·Filed 2021·Granted Nov 8, 2022·6 cites·20 claims
- 0497US9925188B2DNA-PK inhibitors and uses thereofVERTEX PHARMA·Filed 2016·Granted Mar 27, 2018·24 cites·18 claims
- 0597US7208600B2Inhibitors of serine proteases, particularly HCV NS3-NS4A proteasesVERTEX PHARMA·Filed 2004·Granted Apr 24, 2007·129 cites·14 claims
- 0696US9592232B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted Mar 14, 2017·24 cites·13 claims
- 0796US8344153B2Inhibitors of phosphatidylinositol 3-kinaseVERTEX PHARMA·Filed 2010·Granted Jan 1, 2013·47 cites·16 claims
- 0895US9359380B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted Jun 7, 2016·19 cites·25 claims
- 0995US9340557B2Substituted quinoxaline DNA-PK inhibitorsVERTEX PHARMA·Filed 2014·Granted May 17, 2016·19 cites·26 claims
- 1095US9296701B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2013·Granted Mar 29, 2016·21 cites·17 claims
- 1195US7273885B2Inhibitors of serine proteases, particularly HCV NS3-NS4A proteaseVERTEX PHARMA·Filed 2003·Granted Sep 25, 2007·78 cites·29 claims
- 1294US9878993B2DNA-PK inhibitors for treatment of cancerVERTEX PHARMA·Filed 2016·Granted Jan 30, 2018·10 cites·7 claims
- 1393US10786512B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Sep 29, 2020·3 cites·8 claims
- 1492US11077101B1Compounds and methods of useTANGO THERAPEUTICS INC·Filed 2019·Granted Aug 3, 2021·7 cites·43 claims
- 1592US10973830B2Substituted quinoxaline DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Apr 13, 2021·3 cites·23 claims
- 1692US10076521B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2017·Granted Sep 18, 2018·7 cites·21 claims
- 1792US7964624B1Inhibitors of serine proteasesVERTEX PHARMA·Filed 2007·Granted Jun 21, 2011·21 cites·27 claims
- 1892US7365092B2Inhibitors of serine proteases, particularly HCV NS3-NS4A proteaseVERTEX PHARMA·Filed 2004·Granted Apr 29, 2008·40 cites·50 claims
- 1992US7109172B2Inhibitors of serine proteases, particularly HCV NS3-NS4A proteaseVERTEX PHARMA·Filed 2004·Granted Sep 19, 2006·42 cites·13 claims
- 2091US11884672B2Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2020·Granted Jan 30, 2024·4 cites·11 claims
- 2191US10501439B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Dec 10, 2019·5 cites·18 claims
- 2291US10442791B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Oct 15, 2019·5 cites·13 claims
- 2391US10391095B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2018·Granted Aug 27, 2019·5 cites·9 claims
- 2490US9987284B2Substituted benzooxadiazole DNA-PK inhibitorsVERTEX PHARMA·Filed 2016·Granted Jun 5, 2018·5 cites·23 claims
- 2590US7906550B2Inhibitors of serine proteases, particularly HCV NS3-NS4A proteaseVERTEX PHARMA·Filed 2008·Granted Mar 15, 2011·7 cites·4 claims
- 2689US12331057B2Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2023·Granted Jun 17, 2025·1 cites·11 claims
- 2789US10258627B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2017·Granted Apr 16, 2019·4 cites·19 claims
- 2887US12304907B2Compounds and methods of useTANGO THERAPEUTICS INC·Filed 2024·Granted May 20, 2025·0 cites·24 claims
- 2987US12264154B2Compounds and methods of useTANGO THERAPEUTICS INC·Filed 2024·Granted Apr 1, 2025·0 cites·20 claims
- 3087US7985762B2Inhibitors of serine proteasesVERTEX PHARMA·Filed 2006·Granted Jul 26, 2011·8 cites·54 claims
- 3186US12251387B2Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitorsVERTEX PHARMA·Filed 2023·Granted Mar 18, 2025·0 cites·20 claims
- 3286US8354419B2Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2010·Granted Jan 15, 2013·10 cites·23 claims
- 3384US7683033B2Inhibitors of serine proteases, particularly HCV NS3-NS4A proteaseVERTEX PHARMA·Filed 2005·Granted Mar 23, 2010·7 cites·5 claims
- 3483US8039623B2Inhibitors of serine proteases, particularly HCV NS3-NS4A proteaseVERTEX PHARMA·Filed 2007·Granted Oct 18, 2011·5 cites·9 claims
- 3579US11623924B2Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2019·Granted Apr 11, 2023·3 cites·15 claims
- 3678US8440706B2Inhibitors of serine proteasesCOTTRELL KEVIN M·Filed 2011·Granted May 14, 2013·3 cites·12 claims
- 3777US2021236505A1Substituted quinoxaline dna-pk inhibitorsVERTEX PHARMA·Filed 2021·Application pending·0 cites
- 3876US11813267B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2020·Granted Nov 14, 2023·0 cites·19 claims
- 3976US11021465B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted Jun 1, 2021·0 cites·22 claims
- 4075US11008305B2DNA-PK inhibitorsVERTEX PHARMA·Filed 2019·Granted May 18, 2021·0 cites·20 claims
- 4169US8765731B2Benzimidazole analogues for the treatment or prevention of flavivirus infectionsVERTEX PHARMA·Filed 2012·Granted Jul 1, 2014·1 cites·22 claims
- 4269US8372873B2Inhibitors of serine proteasesVERTEX PHARMA·Filed 2011·Granted Feb 12, 2013·1 cites·23 claims
- 4369US2018311254A1Dna-pk inhibitorsVERTEX PHARMA·Filed 2018·Application pending·0 cites
- 4468US2023265080A1Modulators of alpha-1 antitrypsinVERTEX PHARMA·Filed 2023·Application pending·0 cites
- 4564US11986471B2Compounds and methods of useTANGO THERAPEUTICS INC·Filed 2021·Granted May 21, 2024·0 cites·20 claims
- 4664US8426359B2Inhibitors of serine proteases, particularly HCV NS3-NS4A proteaseCOTTRELL KEVIN M·Filed 2008·Granted Apr 23, 2013·0 cites·6 claims
- 4764US2016354381A1Dna-pk inhibitorsObligated Assignee·Filed 2016·Application pending·0 cites
- 4863US2025282749A1Compounds and methods of useTANGO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4963US2010173851A1Inhibitors of serine proteases, particularly hcv ns3-ns4a proteasePITLIK JANOS·Filed 2009·Application pending·0 cites
- 5063US2025171432A1Compounds and methods of useTANGO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 77 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →